681171-56-2

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 184473-60-7 2-(4-bromo-2,5-dimethoxyphenyl)ethanol 
• 7417-19-8 2-(2,5-dimethoxyphenyl)ethanol 
• 128-08-5 N-Bromosuccinimide 
• 681171-54-0 [2-(2,5-dimethoxy-phenyl)-ethoxy]-dimethyl-silane 
• 681171-55-1 tert-butyl-[2-(2,5-dimethoxy-phenyl)-ethoxy]-dimethyl-silane 

Downstream Products

• 762275-83-2 (6-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-2,5-dimethoxy-phenyl}-pyridin-2-yl)-carbamic acid tert-butyl ester 
• 762275-84-3 {6-[4-(2-hydroxy-ethyl)-2,5-dimethoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-89-8 {6-[4-(2-dimethylamino-ethyl)-2,5-dimethoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-85-4 {6-[2,5-dimethoxy-4-(2-oxo-ethyl)-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 894803-86-2 N-(4-amino-5-cyano-6-ethoxy-pyridin-2-yl)-2-(4-methanesulfonyl-2,5-dimethoxy-phenyl)-acetamide 
• 894803-69-1 (4-methanesulfonyl-2,5-dimethoxyphenyl)acetic acid 
• 904311-61-1 2-(4-methanesulfonyl-2,5-dimethoxyphenyl)ethanol 
• 894803-66-8 (4-methanesulfonyl-2,5-dimethoxyphenyl)acetyl chloride 
• 894803-67-9 2-(2,5-dimethoxy-4-methylsulfanylphenyl)ethanol 
• 681171-57-3 C₁₆H₂₉BO₅Si 

Relevant academic research and scientific papers

Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity

The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and irradiation. They have been implicated in the pathology of a variety of different diseases with an inflammatory component including asthma, stroke, Alzheimer's disease, and type 2 diabetes mellitus. In this work, high-throughput screening identified a JNK inhibitor with an excellent kinase selectivity profile. Using X-ray crystallography and biochemical screening to guide our lead optimization, we prepared compounds with inhibitory potencies in the low-double-digit nanomolar range, activity in whole cells, and pharmacokinetics suitable for in vivo use. The new compounds were over 1000-fold selective for JNK-1 and -2 over other MAP kinases including ERK2, p38α, and p38δ and showed little inhibitory activity against a panel of 74 kinases.

Inhibitors of c-Jun N-terminal kinases

The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

2-amino-6-(2,4,5-substituted-phenyl)-pyridines

The invention provides compounds of formula VI and the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are as defined, to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of central nervous system and other disorders. The invention also provides methods for inhibiting neurological damage caused by impairment of glucose and/or oxygen to the brain in a mammal, which method comprises administering to the mammal a NOS inhibitor. In one embodiment, the NOS inhibitor is administered to the mammal prior to surgery, for example prior to cardiac surgery, angioplasty, or angiography.

Substituted 6-phenyl-pyridin-2-ylamines: Selective and potent inhibitors of neuronal nitric oxide synthase

The synthesis and nNOS and eNOS activity of 6-(4-(dimethylaminoalkyl)-/6- (4-(dimethylaminoalkoxy)-5-ethyl-2-methoxyphenyl)-pyridin-2-ylamines and 6-(4-(dimethylaminoalkyl)-/6-(4-(dimethylaminoalkoxy)-2,5-dimethoxyphenyl) -pyridin-2-ylamines 1-8 are described. These compounds are potent inhibitors of the human nNOS isoform.